A B S T R A C T Phagocytosis of urate crystals by human or rabbit neutrophils induces the synthesis and release of a glycoprotein, the crystal-induced chemotactic factor (CCF), which is chemotactically active both in vitro and in vivo. It has been proposed that CCF is a prime mediator of the acute gouty attack. Colchicine has been shown to decrease the production and release of this factor in vitro. In these studies, colchicine, at nonleukopenic doses, is shown to abrogate the acute arthritis induced by monosodium urate crystals in rabbits, but to have no effect upon the arthritis induced by the injection of the purified cell-derived chemotactic factor. Serum colchicine levels were 0.48-0.58 ,uM at 30 min and 0.12-0.3 AM at 90 min after intravenous injection of 0.2 mg/kg colchicine. Peripheral blood polymorphonuclear leukocytes obtained from colchicine-treated animals migrated normally towards a chemotactic stimulus but failed to produce CCF after phagocytosis of monosodium urate crystals. The dialyzed synovial fluid from rabbits injected with microcrystalline sodium urate contained chemotactic activity that was not present when animals were also given intravenous colchicine or injected intra-articularly with the chemotactic factor formyl-methionyl-leucyl-phenylalanine.
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Furthermore, the synovial fluid from rabbits injected with microcrystalline sodium urate significantly decreased 1251-CCF binding to neutrophils. The binding of '25I-CCF to its neutrophil receptor was not significantly reduced by the synovial fluid of colchicinetreated rabbits nor by the synovial fluid ofcontrol rabbits injected with the chemotactic factor formyl-methionylleucyl-phenylalanine. Colchicine (10 and 0.1 AM) was shown to have no effect upon the binding of 125I_CCF to its cell receptor. INTRODUCTION Although colchicine has been used for over a century in the treatment and prevention of gouty arthritis, a complete understanding of its site(s) of action has remained elusive. Colchicine is unique among therapeutic agents used in the treatment of acute arthritis in that its usefulness is generally felt to be relatively limited to this rheumatic disease and that it is not a potent general anti-ihflammatory agent (1-3). Experimentally, colchicine has been demonstrated to dramatically abrogate the inflammatory response to urate crystals in humans (4), but to have only weak effects against induced intradermal staphylococcal infection in guinea pig (5) . In vitro, colchicine and other anti-microtubule agents have been reported to diminish polymorphonuclear leukocyte (PMN)1 chemotaxis (6, 7) and lysosomal enzyme release (8) . However, it seems unlikely that the major in vivo pharmacologic action of colchicine is via either of these mechanisms because neither is unique to urate crystal-induced inflammation, and a drug capable of suppressing such PMN functions would be expected to have more general anti-inflammatory effects than colchicine exhibits. The question therefore remains as to the existence of a relatively unique step in the development of acute urate crystal-induced arthritis which is colchicine-sensitive and of secondary importance in other natural and experimental inflammatory conditions.
Evidence suggests that urate crystal-induced arthritis can develop in the absence of complement (9, 10), Hageman factor (11), and kinins (11); we (12, 13) , and others (14) , have proposed that the initial stimulus in 'Abbreviations used in this paper: BSA, bovine serum albumin; CCF, crystal-induced chemotactic factor; FMLP, formyl-methionyl-leucyl-phenylalanine; MS (15, 16) , or if cells are exposed only to urate in solution (14) . As first reported by Tse and Phelps (17) , the chemotactic activity does not appear if the cells are exposed to colchicine at therapeutic levels before their incubation with urate crystals. More recent studies (15) corroborate and extend these findings to demonstrate that the chemotactic glycoprotein is not detectable in the media or subcellular fractions of colchicine-treated cells allowed to phagocytose urate crystals. It should be noted that phagocytosis per se was not impaired by the colchicine treatment in these experiments. Recent work (18) has shown that the intra-articular injection of the purified urate crystal-induced chemotactic factor (CCF) in rabbits produces a profound arthritis that is histologically identical with that produced by urate crystal injection. However, PMN accumulation in the synovial fluid occurs even more rapidly than in urate crystalinduced arthritis, a finding consistent with the circumvention of the early stages of the inflammatory process consisting of crystal phagocytosis, factor synthesis, and release.
This study presents data indicating that the primary mechanism of colchicine action in ameliorating and preventing the acute gouty attack is by inhibiting the production and(or) release of the cell-derived chemotactic factor which normally mediates the inflammatory response to urate crystals. METHODS Induction of arthritis. Microcrystalline sodium urate (MSU) (0.5-8 microns in length) was prepared as described by Seegmiller et al. (19) . The crystals were heated at 200°C for 1 h to render them pyrogen free (9). 11 female albino rabbits (3-3.5 kg) were injected intravenously with either 0.05, 0.1, or 0.2 mg/kg of colchicine followed 20 min later by the intra-articular injection of 10 mg of MSU suspended in 0.3 ml of isotonic saline in one knee and 0.3 ml isotonic saline alone in the opposite knee. Nine additional rabbits received the intra-articular injections of MSU, but not colchicine, and served as positive controls. Peripheral leukocyte counts were obtained before the colchicine injection, 90 min after, and at the time of sacrifice of the animals, 4 h later. In experiments not presented here, we have found that colchicine at concentrations above 0.2 mg/kg is leukopenic for rabbits and, therefore, higher concentrations were not used in these studies.
In a parallel experiment, eight rabbits were injected with 0.2 mg/kg of colchicine followed by intra-articular injections of 20, 10, or 2 izg of purified CCF in 0.3 ml isotonic saline in one knee and 0.3 ml isotonic saline alone in the opposite knee. The CCF was isolated from rabbit neutrophils allowed to phagocytose MSU as previously described (13 (20) . The ability of the PMN to migrate toward a chemotactic gradient was evaluated by a radioassay that uses Na2 51CrO4 (New England Nuclear, Boston, Mass.) as previously described (13) . Two chemotactic factors were used in the assay, the synthetic peptide formylmethionyl-leucyl-phenylalanine (FMLP) (a generous gift from Dr. Richard J. Freer, Medical College of Virginia, Richmond, Va.) and CCF isolated as previously described (13) . In a separate experiment, the synovial fluid from three rabbits injected intra-articularly with MSU, three injected intra-articularly with MSU and intravenously with 0.2 mg/kg colchicine, and oftwo additional animals injected intra-articularly with 10 nM FMLP in 0.3 ml of saline were centrifuged, and the supernates were dialyzed and tested for their ability to attract PMN in the Boyden chamber at varying concentrations. All synovial fluid samples were dialyzed before performing the chemotactic radioassay. This was done to remove the tripeptide FMLP from synovial fluids. The glycopeptide CCF is not dialyzable (13) .
Generation of cell-derived chemotactic factor. The peripheral blood (60 ml) from three rabbits was collected 90 min after the intravenous injection ofcolchicine (0.2 mg/kg), the PMN were then isolated by Ficoll-Hypaque centrifugation followed by dextran sedimentation and incubated with 5 mg MSU for 45 min at 37°C. The cells were then subjected to the previously described procedure employed to isolate the CCF (13) . The isolated material was tested in the chemotactic chambers. The peripheral blood PMN from two rabbits not injected with colchicine were subjected to the same procedure and used as control.
Determination of serum colchicine levels. Tritiated colchicine (ring C, methoxy-3H, 16 .05 Ci/mmol sp act, in benzene:ethanol) was purchased from New England Nuclear. An aliquot ofthe [3H]colchicine was redissolved in an aqueous solution of 500 ,g/ml unlabeled colchicine which was then injected into three rabbits intravenously (0.2 mg/kg). At stated times serum samples were obtained, and the radioactivity was determined in 10-to 1OO-gl aliquots after the addition of 10 ml of Aquasol-2 (New England Nuclear). The radioactive counts per minute were used to calculate the total colchicine concentration in each of the serum samples. One of the rabbits injected with tritiated colchicine was also injected intraarticularly with 10 mg MSU. At the end of the experiment, 776 I. Spilberg, B. Mandell, J. Mehta, L. Simchowitz, and D. Rosenberg the rabbit was sacrificed and synovial fluid radioactivity determined as described above.
Receptor binding competition assay. CCF was iodinated as described previously (21) . The specific activity of 1251-CCF was 39 ,uCi/Lmol. The knee joint of nine rabbits was injected with 3 mg MSU in 0.3 ml saline (six animals) or 10 nM FMLP in 0.3 ml saline (three animals). Three of the rabbits injected with monosodium urate crystals also received intravenous colchicine (0.2 mg/kg). After 3 h, the animals were sacrificed, and the synovial fluid from the joints was removed, pelleted, and diluted with phosphate-buffered saline. In the binding assays, 1 x 107 human PMN were incubated at 37°C in a total volume of 0.5 ml of Hanks' balanced saline solution, pH 7.4, which contained 0.1% bovine serum albumin (BSA) with either 125I-CCF (final concentration 0.24 J±M) or 1251-CCF and various concentrations of synovial fluid from the animals injected with either crystals, or FMLP which served as control. We have previously shown that FMLP does not compete with 125I-CCF for binding sites in the cell membrane (21) . After 60 min of incubation, 0.5 ml ice-cold Hanks'-0.1% BSA solution was added, followed by centrifugation in a microfuge (model B, Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) at 8,000 g for 2 min. The supernate was discarded, the pellet was resuspended in Hanks'-0.1% BSA, transferred to another tube, and pelleted again. After removing the supernate, the pellet was counted in a gamma counter (NuclearChicago Corp., Des Plaines, Ill.).
In a separate experiment, binding studies of '25I-CCF to human PMN were performed in the presence of 10 and 0.1 tM ofcolchicine. The cells were preincubated with colchicine for 20 min at 370C before the addition of '25I-CCF, and the procedure was conducted as described above.
The binding experiments with [3H]FMLP were performed with the same procedure described for 125I-CCF except that the buffer used was 0.05 Tris-HCl buffer, pH 7.4, which contained 1 mM of MgCl2 (22) . The chemotactic peptide was purchased from New England Nuclear, and had a 57 mCi/ ,umol sp act.
RESULTS
An inflammatory response manifested by intense leukocytic accumulation in the synovial fluid and synovial membrane was observed after the injection of MSU into the knee joint of rabbits. The differential count in the synovial fluid at 4 h showed 95% neutrophils and 5% mononuclear cells. The synovial fluid obtained from saline control joints showed only minimal leukocytosis. The histological evaluation of the synovial membranes from joints injected with crystals demonstrated an inflammatory infiltrate composed of mononuclear cells and neutrophils (figure not shown). When the animals were injected intravenously with colchicine, before the intra-articular injection of crystals, a dose-related decrease in the inflammatory response was noted, as measured by the number of leukocytes present in the synovial fluid as well as the degree of synovial membrane infiltration. The maximal effect was noted with 0.2 mg/kg colchicine (Fig. 1) . No peripheral leukopenia at this colchicine concentration was noted. Colchicine, when injected at concentrations higher than 0.2 mg/kg was noted to be leukopenic for the rabbits. When the rabbits were injected with 2, 10, or 20 ,ug of the CCF, an inflammatory response indistinguishable from that induced by crystals was noted. Pretreatment with colchicine, however, had no effect upon the inflammatory reaction in response to the purified factor (Table I) .
The peripheral blood PMN from three rabbits, collected immediately preceding and 90 min after the administration of colchicine, were tested for their ability to migrate towards a chemotactic factor gradient and to generate CCF in vitro after phagocytosis of urate crystals. Although no difference in the chemotactic behavior of the cells was noted when challenged with FMLP or CCF in the Boyden chamber (Table II) The synovial fluid obtained from rabbits injected intra-articularly with MSU was tested for its ability to attract human neutrophils in vitro (Table III) and to compete with human 1251-CCF for binding sites present on the human neutrophils (Table IV) . The synovial fluid samples were dialyzed before the chemotactic assays. In the binding experiments, the synovial fluid samples were not dialyzed. The synovial fluid from rabbits injected intra-articularly with MSU was shown to attract human neutrophils at dilutions of 1 In experiments designed to investigate the possible effect of colchicine upon 1251-CCF binding to human neutrophils, the binding studies were performed employing cells preincubated with the drug at concentrations of 10 The serum levels of colchicine were measured in three rabbits. The concentration range obtained in the animals were as follows: at 15 min after injection, the colchicine levels were 0.83-4 ,uM; at 30 min, the levels had decreased to 0.48-0.58 ,uM and continued to decline slowly throughout the duration ofthe experiment (Fig. 2) . One of the rabbits was also injected with MSU (10 mg) intra-articularly, and the colchicine levels measured in its synovial fluid was found to be (23, 24) . It seems likely that the anti-inflammatory effect of colchicine is directed towards an early step in the development of the inflammatory response induced by urate crystals. In vitro studies (15, 17) have shown that colchicine-treated cells can phagocytose MSU crystals, a prerequisite for the appearance of chemotactic activity (25) , but the release and(or) granule localization of the factor is prevented (15, 17) . Likewise, in this study the peripheral blood neutrophils obtained from colchicine-treated rabbits, although able to phagocytose crystals in vitro, failed to show detectable chemotacticfactor activity in chromnatographic cell fractions. These results may suggest a direct or indirect effect of colchicine on the synthetic apparatus of the cell, an effect reported in other cell systemiis (26) . Selective effects of colchicine on protein secretion and intracellular localization have also been reported (8, 27) .
Chemotactic activity was demonstrated to be present in the dialyzed synovial fluid of animals injected intraarticularly with MSU, but only minimnal activity was demonstrated in the dialyzed synovial fluid of rabbits pretreated with colchiciiie or in the dialyzed synovial fluid of control rabbits injected intra-articuilarly with FMLP. When the synovial fluid of animnals injected intra-articularly with MISU was incubated with '251-CCF and cells, a dose-related decrease of 1251-CCF binding to the cells was noted. This decrease in binding was markedly reduced when the synovial fluid of colchicinetreated rabbits was tested, or when the synovial fluid obtained from rabbits injected with FMLP intraarticularly was incubated with '25I-CCF and cells.
Colchicine, at concentrations of 10 (21) . The data stummarized above would indicate the appearance of CCF in vivo in the synovial fluid of the animnals injected with MSU. The presence of a chemotactic, stereochemiiically related substance(s) able to bind to the CCF receptor on the neuitrophil and present in the synovial fluid of NISU-injected rabbits, but not in the controls, wouild appear unlikely.
Because the control synovial fluid obtained from animals injected with FMLP contained a similar number of cells before they were removed before the assay, the possibility of neutrophil-derived peptidases being responsible for lowering 125I-CCF binding relative to control levels is also unlikely. Furthermore, the synovial fluid from MSU-injected rabbits did not lower the binding of [3H]FMLP to the cells.
The serum level ofcolchicine at 30 min was _0. 1 ,uM and remained so during the duration ofthe experiment. This colchicine concentration, which approximates that obtainable in man with therapeutic doses of colchicine (2) , has been reported to impair the in vitro appearance of CCF after interaction of PMN with MSU (12, 15, 17) .
In summary, data are presented which support the postulate that the therapeutic efficacy of colchicine in gout and experimental urate crystal-induced arthritis is related to the suppression of chemotactic factor generation and release by the neutrophil. Presumably, colchicine is not a more potent general antiinflammatory agent because in many other inflammatory states, in contradistinction to crystal-induced arthritis, the neutrophil-derived chemotactic factor is not a major mediator, and therefore its suppression by colchicine only modestly abrogates the inflammatory process. Our data also demonstrate the presence of a chemotactic factor with similar, ifnot identical, characteristics than human CCF in synovial fluid of rabbits injected with MSU.
